Neurotrophin Signaling Pathways In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurotrophins are a family of growth factors that play critical roles in neuronal survival, development, function, and plasticity. The neurotrophin family includes brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). These signaling pathways become dysregulated in neurodegenerative diseases, making them important therapeutic targets.
flowchart TD
A[Neurotrophin: BDNF<br/>NGF<br/>NT-3<br/>NT-4] --> B[p75NTR Receptor] -->
A --> C[Trk Receptors:<br/>TrkA<br/>TrkB<br/>TrkC] -->
B --> D[NF-κB Pathway:<br/>Cell Survival<br/>Apoptosis] -->
B --> E[JNK Pathway:<br/>Apoptosis] -->
B --> F[SMAD Pathway:<br/>Differentiation] -->
C --> G[Ras/Raf/MEK/ERK:<br/>Cell Survival<br/>Differentiation] -->
C --> H[PI3K/Akt:<br/>Cell Survival<br/>Metabolism] -->
C --> I[PLC-γ:<br/>Calcium Signaling<br/>Synaptic Plasticity] -->
G --> J[CREB:<br/>Gene Transcription<br/>Synaptic Plasticity] -->
H --> K[mTOR:<br/>Protein Synthesis<br/>Autophagy] -->
D --> L[Neuronal Survival] -->
E --> M[Apoptosis)
J --> N[Synaptic Plasticity<br/>Memory Formation] -->
K --> O[Axonal Growth<br/>Regeneration] -->
L --> P[Neuroprotection)
N --> P
O --> P
| Neurotrophin |
Primary Receptor |
Primary Functions |
| BDNF |
TrkB |
Synaptic plasticity, memory, neuronal survival |
| NGF |
TrkA |
Sensory neuron survival, cholinergic function |
| NT-3 |
TrkC |
Motor neuron development, synaptic function |
| NT-4 |
TrkB |
Neuronal survival, synaptic plasticity |
- Trk receptors (TrkA, TrkB, TrkC): Tyrosine kinase receptors that mediate pro-survival signaling
- p75NTR: Pan-neurotrophin receptor that can promote either survival or apoptosis depending on context and co-receptor expression
- Ras/Raf/MEK/ERK: MAPK pathway for cell survival and differentiation
- PI3K/Akt: Critical pro-survival pathway
- PLC-γ: Calcium signaling and synaptic plasticity
- CREB: Transcription factor for neuroplasticity genes
In Alzheimer's disease, BDNF signaling is impaired at multiple levels:
- Reduced BDNF expression: Aβ oligomers and tau pathology downregulate BDNF gene expression
- Impaired TrkB signaling: Aβ interferes with TrkB receptor signaling and trafficking
- Decreased CREB activation: Leads to impaired synaptic plasticity and memory formation
- p75NTR alterations: Changed p75NTR expression affects neuronal survival
- BDNF delivery: Recombinant BDNF or gene therapy approaches
- Small molecule TrkB agonists: Designed to enhance downstream signaling
- Exercise-induced BDNF: Voluntary exercise increases hippocampal BDNF
- Nutraceuticals: Certain compounds (resveratrol, curcumin) may enhance BDNF
In Parkinson's disease, neurotrophin signaling deficits contribute to dopaminergic neuron vulnerability:
- Reduced BDNF: The substantia nigra shows decreased BDNF expression
- Impaired NGF signaling: Cholinergic dysfunction in PD
- Trk receptor dysfunction: Altered signaling in surviving neurons
- GDNF and Neurturin: Growth factors that support dopaminergic neurons
- AAV-BDNF delivery: Gene therapy approaches
- TrkB/TrkA agonists: Small molecule activation
- Exercise and environmental enrichment: Endogenous BDNF enhancement
ALS shows selective vulnerability of motor neurons related to neurotrophin signaling:
- Impaired Trk signaling: Decreased survival signaling in motor neurons
- p75NTR alterations: Dysregulated apoptosis signaling
- Neurotrophin deficits: Reduced support for motor neurons
- CNTF (Ciliary Neurotrophic Factor): Clinical trials in ALS
- BDNF delivery: Initial trials showed limited efficacy
- TrkB agonists: Investigational approaches
- Combination therapies: Targeting multiple pathways
Huntington's disease shows specific neurotrophin signaling impairments:
- BDNF transport deficits: Mutant huntingtin impairs BDNF transport
- Reduced TrkB signaling: Decreased pro-survival signaling
- p75NTR upregulation: Increased pro-apoptotic signaling
- CREB dysfunction: Impaired transcriptional regulation
- BDNF enhancement: Gene therapy and small molecule approaches
- TrkB modulators: Activate downstream signaling
- p75NTR antagonists: Reduce pro-apoptotic signaling
- Restoring BDNF transport: Targeting vesicular transport
| Strategy |
Example |
Status |
| Trk receptor agonists |
7,8-DHF, amitriptyline |
Preclinical/clinical |
| BDNF mimetics |
Small molecule BDNF mimics |
Preclinical |
| p75NTR antagonists |
RAGE ligands |
Preclinical |
| PDE inhibitors |
Increase cAMP/CREB |
Clinical trials |
- AAV-BDNF: Delivering BDNF to target neurons
- AAV-NGF: Supporting cholinergic neurons in AD
- Gene editing: Targeting neurotrophin genes
- Exercise: Increases hippocampal BDNF
- Calorie restriction: May enhance neurotrophin signaling
- Cognitive enrichment: Activity-dependent BDNF release
- Sleep: Sleep deprivation reduces BDNF
- Reduced serum BDNF in AD and PD patients
- Correlates with cognitive decline
- Potential for monitoring treatment response
- CSF BDNF levels in neurodegenerative diseases
- NGF levels in cholinergic dysfunction
- NT-3 in motor neuron diseases
- Blood-brain barrier penetration: Developing CNS-deliverable neurotrophins
- Selective TrkB activation: Avoiding p75NTR-mediated effects
- Combination therapies: Neurotrophins with other interventions
- Biomarker development: For patient selection and response monitoring
The study of Neurotrophin Signaling Pathways In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11(6):1164-1178. DOI:10.5114/aoms.2015.56342
-
Allen SJ, Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin Sci (Lond). 2006;110(2):175-191. DOI:10.1042/CS20050191
-
Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, Kudo H. BDNF function and intracellular signaling in neurons. Histol Histopathol. 2010;25(2):237-258. DOI:10.14670/HH-25.237
-
Chao MV, Bothwell M. Neurotrophins: to cleave or not to cleave. Neuron. 2002;33(1):9-12. DOI:10.1016/s0896-6273(0200556-3
-
Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem. 2003;72:609-642. DOI:10.1146/annurev.biochem.72.121801.161629
-
Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005;6(8):603-614. DOI:10.1038/nrn1726
-
Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol. 2007;81(5-6):294-330. DOI:10.1016/j.pneurobio.2007.01.003
-
Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10(3):209-219. DOI:10.1038/nrd3366
-
Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci. 2006;29:507-538. DOI:10.1146/annurev.neuro.29.051605.112929
-
Hempstead BL. Dissecting the diverse actions of pro- and mature neurotrophins. ACS Chem Neurosci. 2015;6(1):51-61. DOI:10.1021/cn5002623
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%